FDA Grants Soligenix (SNGX.OB) "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients With Head and Neck Cancer
6/3/2013 11:12:28 AM
More...
|
Soligenix (SNGX.OB) Announces Issuance of US Patent for Its ThermoVax™ Technology
5/22/2013 9:58:02 AM
More...
|
Soligenix (SNGX.OB) Initiates Phase 1 Clinical Study With SGX203 for the Treatment of Pediatric Crohn's Disease
5/15/2013 9:16:11 AM
More...
|
Soligenix (SNGX.OB) Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
5/3/2013 7:39:44 AM
More...
|
Soligenix (SNGX.OB) and Intrexon Corporation Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
5/1/2013 10:19:51 AM
More...
|
Soligenix (SNGX.OB) to Present at World Vaccine Congress & Expo
4/16/2013 7:47:47 AM
More...
|
Soligenix (SNGX.OB) Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
3/27/2013 10:16:51 AM
More...
|
Soligenix (SNGX.OB) Announces Significant Progress With ThermoVax™ Towards the Development of Heat Stable Vaccines
3/19/2013 9:47:50 AM
More...
|
Soligenix (SNGX.OB) Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
2/26/2013 6:28:30 AM
More...
|
Soligenix (SNGX.OB) Submits BARDA Contract Proposal for Development of OrbeShield™ in GI ARS
2/20/2013 10:23:49 AM
More...
|
|